Displaying drugs 14251 - 14275 of 15222 in total
U-0126
U-0126 is a direct inhibitor of the mitogen-activated protein-kinase kinase family members, MEK-1 and MEK-2.
Investigational
Matched Description: … U-0126 is a direct inhibitor of the mitogen-activated protein-kinase kinase family members, MEK-1 and …
Emprumapimod
Emprumapimod is a potent, orally active and selective inhibitor of p38α mitogen-activated kinase inhibitor. It was investigated for dilated cardiomyopathy.
Investigational
Matched Description: … Emprumapimod is a potent, orally active and selective inhibitor of p38α mitogen-activated kinase inhibitor …
Ensitrelvir
Ensitrelvir is under investigation in clinical trial NCT05605093 (Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor (Ensitrelvir)).
Investigational
Matched Description: … Ensitrelvir is under investigation in clinical trial NCT05605093 (Strategies and Treatments for Respiratory …
Befotertinib
Befotertinib is under investigation in clinical trial NCT05007938 (Befotertinib and Icotinib in Treatment-naive Patients With Advanced Egfr-mutant Lung Cancer).
Investigational
Matched Description: … Befotertinib is under investigation in clinical trial NCT05007938 (Befotertinib and Icotinib in Treatment-naive …
Rifasutenizol
Rifasutenizol is under investigation in clinical trial NCT05857163 (Efficacy and Safety of Rifasutenizol (TNP 2198) in Participants With H. Pylori Infection).
Investigational
Matched Description: … Rifasutenizol is under investigation in clinical trial NCT05857163 (Efficacy and Safety of Rifasutenizol …
Indirubin-3'-monoxime
Experimental
2-Amino-3-(1h-Indol-3-Yl)-Propan-1-Ol
Experimental
Arimoclomol
Arimoclomol is an experimental drug compound developed by CytRx Corporation, a biopharmaceutical company based in Los Angeles, California. The orally administered drug is intended to treat amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, a neurodegenerative disease with no effective treatment.
Investigational
Pipendoxifene
ER modulator, ERA-923(Pipendoxifene) is a estrogen receptor modulator being evaluated for the treatment of breast cancer. Pipendoxifene is a new 2-phenyl indole selective estrogen receptor modulators (SERM )that exhibits an excellent preclinical pharmacological profile and was selected for further development as a treatment for metastatic breast cancer.
Investigational
Matched Description: … estrogen receptor modulators (SERM )that exhibits an excellent preclinical pharmacological profile and …
4-O-Demethylpenclomedine
Investigational
2-heptyl-4-hydroxyquinoline N-oxide
Experimental
9-(3-IODOBENZYLAMINO)-1,2,3,4-TETRAHYDROACRIDINE
Experimental
2-(2-METHYLPHENYL)-1H-INDOLE-5-CARBOXIMIDAMIDE
Experimental
(3E)-4-(1-METHYL-1H-INDOL-3-YL)BUT-3-EN-2-ONE
Experimental
Displaying drugs 14251 - 14275 of 15222 in total